Clinical trials: Oligometastasis, open to volunteers
Oligometastasis, Oligometastatic Disease
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
This study is for participants whose cancer is oligometastatic, meaning it has spread to up to five spots in their body and their doctor recommends that they have stereotactic body radiation therapy (SBRT) to treat these cancer…
- Trial name
- NCT07079098
- Testing
- Simulation-free workflow, SBRT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Oligometastasis
Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
A Randomized, Open Label, Phase III Trial to Evaluate Radical Local Treatment versus Palliative Treatment for Breast Cancer Patients with Primary Ipsilateral Humerus or Sternum Oligometastasis
- Trial name
- BOMB (NCT04158843)
- Testing
- Radical resection, Radical radiotherapy, Palliative treatment
- Where
- 4 sites in China
- Volunteers
- 183 people
- Sponsor
- xuexin he
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Oligo-metastatic Prostate Carcinoma
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative…
- Conditions
- Prostate Cancer, Oligo-metastatic Prostate Carcinoma, Oligometastatic Cancer, Nodal Oligorecurrent Prostate Cancer
- Trial name
- PINPOINT (NCT07635108)
- Testing
- Single-fraction SBRT
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Odense University Hospital
Breast Cancer
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free…
- Trial name
- LARA (NCT04698252)
- Testing
- Radiotherapy, Surgery, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute
Oligometastasis, Metastatic Cancer
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
- Trial name
- NCT04085029
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Adenocarcinoma, Stomach Neoplasm
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of radiotherapy combined with chemotherapy and anti-PD-1 immunotherapy followed by surgery for the primary and metastatic lesions in patients with limited…
- Conditions
- Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
- Trial name
- Miracle-G (NCT06121700)
- Testing
- Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
This phase I/II trial tests the safety and efficacy of split-course adaptive radiation therapy in combination with immunotherapy with or without chemotherapy for the treatment of patients with stage IV lung cancer or lung cancer…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
- Trial name
- NCT05501665
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pancreatic Cancer Non-resectable
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer.
- Trial name
- NCT07386704
- Testing
- Nimotuzumab combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Urothelial Carcinoma (UC)
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options…
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Oligometastasis
- Trial name
- ASTRA (NCT07413523)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
- Trial name
- STROKER (NCT06726421)
- Testing
- Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
- Where
- 9 sites in China
- Volunteers
- 252 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer Stage IV
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
Cervical cancer is one of the most malignant reproductive system tumors that threaten women's health, characterized by distinct HPV-driven carcinogenesis and immunosuppressive tumor microenvironment.
- Trial name
- NCT06998394
- Testing
- AK104 - Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangbo Wan
Esophageal Cancer
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
This study aims to evaluate the efficacy and safety of bemosubabimab combined with anlotinib and radiotherapy and chemotherapy in the treatment of patients with oligometastatic esophageal cancer.
- Trial name
- NCT07455019
- Testing
- The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Oncology, Tumor Recurrence and Metastasis
Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
The main objective of this study was to evaluate the effect of surgical margin width on the prognosis of patients with hepatic oligometastasis of colorectal cancer by statistical 1-year intrahepatic recurrence-free survival rate…
- Trial name
- NCT06934018
- Testing
- Surgery and procedure
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University
Advanced Hepatocellular Carcinoma, Lung Cancer
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…
- Conditions
- Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
- Trial name
- NCT06644430
- Testing
- Ablation, system therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Sun Yat-sen University
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center